Menu

Refactual

We publish EVERYTHING sent to publish@refactual.com

Lonza Expands Bioconjugation Facility, Opiant and Sanofi to Manufacture Cannabinoid Overdose Treatment, and More in Today’s CP Direct

 

Lonza Expands Bioconjugation Facility, Opiant and Sanofi to Manufacture Cannabinoid Overdose Treatment, and More in Today’s CP Direct
 Trouble viewing this email? Read it online
Follow us on:       
July 24, 2019
Magazine  I  News  I  Research  I  Directory  I  Topics  I  Classifieds  I  Resources  I  Provider Microsites
Sponsored by Nelson Labs

FEATURED NEWS


Lonza Expands Bioconjugation Facility and Third Commercial ADC Approved
Expansion of bioconjugation in Visp to meet increasing clinical, launch and commercial market demand
Read More >>

Opiant Pharmaceuticals, Sanofi to Manufacture Acute Cannabinoid Overdose Treatment
Opiant’s drinabant, selective cannabinoid receptor antagonist, could be first approved treatment for ACO
Read More >>

Five Reasons to Outsource API Procurement
An expert partner can get you access, add quality and speed to your supply chain, and more. Read our white paper about taking on an API sourcing, distribution, and supply chain specialist.
Learn More >>

LATEST STORIES


PRA Health Sciences Buys Out Joint Venture in Japan
Acquires expert staff members from Takeda
Read More >>

WuXi STA Facilities Pass U.S. FDA Inspections
Analytical Service Unit in Shanghai and API manufacturing facility in Changzhou successfully pass inspections
Read More >>

[TOMORROW] Designing an End-to-End Sterility Assurance Program
Join us tomorrow, July 25th, for a live webinar as we address the various aspects of sterility assurance and provide guidance on establishing a complete program.
Register Now >>

Syapse, Pfizer in Oncology Precision Medicine Pact
To focus on outcomes research using Real-World Evidence
Read More >>

Cytena Establishes Subsidiary in Taiwan
Cytena Bioprocess Solutions aims to increase efficiency in cell line development
Read More >>

Are We Embracing FDA’s Message?
FDA guidance on analytical procedures and methods validation for drugs and bilogics.
Read More >>

Boehringer Ingelheim, Bridge Biotherapeutics to Collaborate on IPF Pipeline
Global license agreement aims to develop Bridge Biotherapeutics’ autotaxin inhibitor, BBT-877
Read More >>

Abzena Completes ADC Tech Transfer
Successful technical transfer of Synaffix GlycoConnect ADC Technology to enable use in client projects
Read More >>

   
CURRENT ISSUE
July/August 2019

Latest Issue Check out the feature
content
from the latest issue.

CASE STUDY SPOTLIGHT

 

Recro

Cost-Effective Solution to Filing Your CMC Supplement
Opioid Reformulation for Abuse Deterrence — Filed as a CMC Supplement in Less Than a Year

Microsite Spotlight

meet-iqvia
Ajinomoto Bio-Pharma Services
Ajinomoto Bio-Pharma Services is a fully integrated CDMO providing comprehensive process development services, cGMP manufacturing and drug product fill finish services of small molecule and biologic APIs and intermediates.
White Papers / Tech Papers



We hope you enjoyed this edition of Contract Pharma Direct’s Newsletter

You are receiving this message because you opted in at contractpharma.com. To change your preferences or unsubscribe please use the links below.

To ensure delivery and proper display of your emails, please add our email address (cp@email.contractpharma.com) to your address book and if needed enable images in your email client.

To update your user profile please click here.

To unsubscribe or change your email subscription preferences please click here.

If you are having trouble with receiving Contract Pharma Magazine or would like to receive it, click here.

Advertise with us

Our mailing address is:

Contract Pharma
Rodman Media
25 Philips Parkway, Montvale, NJ 07645 USA
Tel: 201-825-2552, Fax: 201-825-0553

© Copyright 2019 Contract Pharma All rights reserved.


Leave a Reply